T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …

Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …

Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

Neoantigens arise from mutations in cancer cells and are important targets of T cell-
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a …

Within the tumour microenvironment, CD4+ T cells can promote or suppress antitumour
responses through the recognition of antigens presented by human leukocyte antigen (HLA) …

Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …

BACKGROUND Therapeutic vaccinations against cancer have mainly targeted
differentiation antigens, cancer-testis antigens, and overexpressed antigens and have thus …

Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer
regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors …